Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) announced a conference call on March 6, 2023, at 4:30 p.m. EST to discuss its fourth quarter and full year 2022 financial results along with a corporate update. The company is recognized for its KORSUVA® injection, the first FDA-approved treatment for pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Cara is actively developing an oral formulation of difelikefalin and has begun Phase 3 trials for non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. A Phase 2 trial for notalgia paresthetica was recently completed, with plans for a Phase 2/3 trial starting in Q1 2023.

Positive

• First FDA-approved treatment for pruritus in chronic kidney disease
• Development of oral difelikefalin with ongoing Phase 3 trials
• Completed Phase 2 trial for notalgia paresthetica, with new trials planned

Negative

• None.

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What date will Cara Therapeutics report its 2022 financial results?

Cara Therapeutics will report its 2022 financial results on March 6, 2023.

What product is Cara Therapeutics known for?

Cara Therapeutics is known for KORSUVA® (difelikefalin), the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

Is Cara Therapeutics involved in clinical trials?

Yes, Cara Therapeutics is conducting Phase 3 trials for its oral formulation of difelikefalin and has initiated other clinical trials.